Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: July 2013 HCV Advocate Newsletter


Senior Member

Status: Offline
Posts: 102
Date:
RE: July 2013 HCV Advocate Newsletter
Permalink  
 


The Gilead trial seems very promising for people!

~

Carol



__________________

Husband has HCV.  Viral load @ start of treatment was 1,600,000.  Genotype 2.

Treatment includes Ribavirin pills and Peginterferon injections for 24 weeks.

UND at 4 weeks, 12 weeks and EOT plus 1.5 weeks and 3 months. 



Guru

Status: Offline
Posts: 3398
Date:
Permalink  
 

Obviously I'm not a Research Scientist, but I'm having real trouble with the antiprotease resistant mutations. We have Simeprevir getting FDA fast-tracking, but it has the same problems with mutations as Victrelis and Incivek.  However Merck's MK-5172 has been virtually ignored. It is effective against the mutations that cause problems with Victrelis ( mutations V36M, T54S and R155K) which is why it gives better SVR results. It could also be used as repeat antiprotease Rx as the mutations present in Victrelis failures would not be a problem. Admittedly it needs Peg and Riba at present, but only for 24 weeks (even in cirrhotics and Geno 1a's). Perhaps Sofosbuvir is getting too much attention.



__________________

Geno 1b, IL28B CT,  x3 prior relapser,  ex-cirrhotic, 75 yo, did 48 weeks with Victrelis/Peg./Riba.  VL 1.28m at start, UNDET. at 8 ,12 ,16 ,24 ,30  and 48 weeks.  EOT 15 Feb 2013 , UNDET. at EOT + 28 weeks. SVR!  Still Undet. at EOT +5 years

Malcolm



Guru

Status: Offline
Posts: 3398
Date:
Permalink  
 

Hi Jill,

There is a very good article 'DAA's look good...........' in the Newsletter. If you can wade through it, it gives a very thorough account of the drug-mutation problems for the antiproteases.  Merck's new antiprotease MK-5172 has excellent resistance to mutation, which explains the very good results for all Geno 1's. It appears to be the best NS-3/4A blocker by a long way, and although the Trials used Peg and Riba, it could be combined with sofosbuvir to create a top-class combo. It appears to be much more potent that dear old Victrelis, with much better SVR rates.

I wish more Drug Companies would release data about resistant mutations to their products, but perhaps they don't want to.



__________________

Geno 1b, IL28B CT,  x3 prior relapser,  ex-cirrhotic, 75 yo, did 48 weeks with Victrelis/Peg./Riba.  VL 1.28m at start, UNDET. at 8 ,12 ,16 ,24 ,30  and 48 weeks.  EOT 15 Feb 2013 , UNDET. at EOT + 28 weeks. SVR!  Still Undet. at EOT +5 years

Malcolm



Guru

Status: Offline
Posts: 5627
Date:
Permalink  
 

Yes, it`s a useful article, Malcolm.  What you`re saying about antiprotease resisitant mutations makes good sense, and it`s interesting about the potential benefit of using of Merck`s Mk-5172 as a retreatment drug, especially when someone has previously failed with victrelis.  Otherwise a lot of people are going to be relying on Sofosbuvir, as it stands.  Odd that we don`t hear much about it when Simeprevir is being given priority status by the FDA, yes.  It will be interesting to see how things develop over the next year or so, and which new drug combos come to fruition.  Thanks for your comments, astute as always.



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 



Guru

Status: Offline
Posts: 5627
Date:
Permalink  
 

July 2013 HCV Advocate Newsletter

http://www.hcvadvocate.org/news/newsLetter/2013/advocate0713.html

 

 



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.